Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab and Temozolomide in Recurrent/Refractory SCLC and Advanced Neuroendocrine Tumors
NCT03728361Phase 2Completed
- Start
- Dec 2018
- Primary completion
- Dec 2025
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab and temozolomide in small cell lung cancer (SCLC) and neuroendocrine carcinoma (NEC). Primary endpoint: Objective Response Rate up to 3 years. Started Dec 2018; status: completed.
02
Drugs
nivolumabtemozolomide
03
Conditions
small cell lung cancer (SCLC)neuroendocrine carcinoma (NEC)
Beyond the preview
Go deeper on NCT03728361.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03728361.